We have previously shown in neuroblastoma cells that YM155 activates p53 signaling, that p53 activation using MDM2 inhibitors enhances the YM155 effects, and that p53 depletion reduces cancer cell sensitivity to YM155 [15]. Here, TP53 is linked to cancer.